X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (13) 13
oncology (13) 13
breast cancer (12) 12
chemotherapy (8) 8
female (8) 8
humans (8) 8
cancer (7) 7
survival (7) 7
trastuzumab (7) 7
adult (6) 6
aged (6) 6
erbb-2 protein (6) 6
middle aged (6) 6
metastases (5) 5
metastasis (5) 5
therapy (5) 5
breast neoplasms - drug therapy (4) 4
breast neoplasms - mortality (4) 4
epidermal growth factor (4) 4
life sciences (4) 4
patients (4) 4
aged, 80 and over (3) 3
benign (3) 3
breast neoplasms - genetics (3) 3
clinical trials (3) 3
emission-computed (3) 3
genome-wide association (3) 3
her2 (3) 3
hybrid imaging (3) 3
metastatic breast cancer (3) 3
musculoskeletal diseases (3) 3
overall survival (3) 3
prospective studies (3) 3
radionuclide bone scanning (3) 3
survival analysis (3) 3
tomography (3) 3
tumors (3) 3
young adult (3) 3
[sdv.can]life sciences [q-bio]/cancer (2) 2
analysis (2) 2
analysis of variance (2) 2
antineoplastic agents - administration & dosage (2) 2
association (2) 2
bevacizumab (2) 2
biomarkers, tumor (2) 2
brain metastases (2) 2
breast neoplasms - chemistry (2) 2
breast neoplasms - pathology (2) 2
care and treatment (2) 2
central nervous system (2) 2
chemotherapy, adjuvant (2) 2
clinical trials, phase iii as topic (2) 2
cohort studies (2) 2
confidence intervals (2) 2
diagnosis (2) 2
follow-up (2) 2
france - epidemiology (2) 2
genetic predisposition to disease (2) 2
genomes (2) 2
hematology, oncology and palliative medicine (2) 2
kaplan-meier estimate (2) 2
male (2) 2
medical prognosis (2) 2
neoadjuvant (2) 2
neoplasm metastasis (2) 2
nervous system (2) 2
paclitaxel (2) 2
patient outcomes (2) 2
polymorphism, single nucleotide (2) 2
prognosis (2) 2
randomized controlled trials as topic (2) 2
receptor, erbb-2 - analysis (2) 2
receptor, erbb-2 - genetics (2) 2
risk (2) 2
single-photon computed tomography (2) 2
skin and connective tissue diseases (2) 2
studies (2) 2
subtypes (2) 2
susceptibility loci (2) 2
time factors (2) 2
treatment outcome (2) 2
variants (2) 2
women (2) 2
1st-line chemotherapy (1) 1
[ sdv ] life sciences [q-bio] (1) 1
[ sdv.can ] life sciences [q-bio]/cancer (1) 1
[ sdv.spee ] life sciences [q-bio]/santé publique et épidémiologie (1) 1
[sdv.can] life sciences [q-bio]/cancer (1) 1
[sdv.spee] life sciences [q-bio]/public health and epidemiology (1) 1
[sdv.spee]life sciences [q-bio]/santé publique et épidémiologie (1) 1
[sdv]life sciences [q-bio] (1) 1
adjuvant (1) 1
adjuvant trastuzumab (1) 1
adults (1) 1
alleles (1) 1
american-society (1) 1
angiogenesis inhibitor (1) 1
angiogenesis inhibitors - adverse effects (1) 1
angiogenesis inhibitors - therapeutic use (1) 1
anthracycline (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet Oncology, The, ISSN 1470-2045, 2013, Volume 14, Issue 8, pp. 741 - 748
Summary Background Since 2005, 12 months of adjuvant trastuzumab has been the standard treatment for patients with HER2-positive early-stage breast cancer.... 
Hematology, Oncology and Palliative Medicine | ONCOLOGY | FOLLOW-UP | CHEMOTHERAPY | Breast Neoplasms - surgery | Predictive Value of Tests | Breast Neoplasms - secondary | Receptor, ErbB-2 - genetics | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Antineoplastic Agents - administration & dosage | Protein Kinase Inhibitors - adverse effects | Young Adult | Breast Neoplasms - chemistry | Antibodies, Monoclonal, Humanized - administration & dosage | Neoplasms, Second Primary | Time Factors | Antineoplastic Agents - adverse effects | Aged, 80 and over | Mastectomy | Adult | Female | Chemotherapy, Adjuvant | France | Heart Diseases - chemically induced | Radiotherapy, Adjuvant | Antibodies, Monoclonal, Humanized - adverse effects | Drug Administration Schedule | Early Detection of Cancer | Kaplan-Meier Estimate | Neoplasm Recurrence, Local | Proportional Hazards Models | Treatment Outcome | Breast Neoplasms - drug therapy | Disease-Free Survival | Protein Kinase Inhibitors - administration & dosage | Breast Neoplasms - genetics | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Breast Neoplasms - mortality | Aged | Infusions, Intravenous | Receptor, ErbB-2 - analysis | Trastuzumab | Antimitotic agents | Care and treatment | Clinical trials | Breast cancer | Product development | Antineoplastic agents | Cancer
Journal Article
Breast Cancer Research, ISSN 1465-5411, 08/2017, Volume 19, Issue 1, p. 98
Journal Article
BRITISH JOURNAL OF CANCER, ISSN 0007-0920, 12/2019, Volume 121, Issue 12, pp. 991 - 1000
BACKGROUND: Metastatic breast cancer (MBC) behaviour differs depending on hormone receptors (HR) and human epidermal growth factor receptor (HER2) statuses.... 
SURVIVAL | THERAPY | ONCOLOGY | CNS METASTASES | BRAIN METASTASES | VALIDATION | HER2 STATUS | OUTCOMES | SOCIETY | ADJUVANT TRASTUZUMAB | FEATURES | Index Medicus
Journal Article
Oncotarget, ISSN 1949-2553, 2016, Volume 7, Issue 47, pp. 77358 - 77364
Journal Article
NPJ BREAST CANCER, ISSN 2374-4677, 02/2017, Volume 3, Issue 1, p. 4
Human epidermal growth factor receptor 2-positive breast cancer is a subtype of interest regarding its outcome and the impressive impact of human epidermal... 
SUSCEPTIBILITY LOCI | RISK | TRASTUZUMAB | ONCOLOGY | MEAN TELOMERE LENGTH | GENOME-WIDE ASSOCIATION
Journal Article
European Journal of Cancer, ISSN 0959-8049, 06/2018, Volume 96, pp. 17 - 24
Journal Article
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 05/2019, Volume 37, Issue 15_suppl, pp. 11566 - 11566
11566 Background: CANTO (CANcer TOxicities - NCT01993498) is a French multicenter prospective longitudinal study dedicated to the quantification and... 
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 05/2019, Volume 37, Issue 15_suppl, pp. 3019 - 3019
3019 Background: Circulating Tumor Cells (CTC) are independent markers of progression-free survival (PFS) and overall survival (OS) in patients (pts) with... 
Journal Article